Use of oral ganciclovir for cytomegalovirus retinitis. (adapted from the New England Journal of Medicine 1995;333:615-20)(Tips from Other Journals)

From: American Family Physician | Date: January 1, 1996 | Copyright information

Retinitis, a complication in 40 percent of patients with acquired immunodeficiency syndrome, may lead to partial or complete vision loss if left untreated. Intravenous ganciclovir and foscarnet are approved treatments for cytomegalovirus retinitis. However, intravenous therapy is associated with substantial cost, inconvenience and risk of catheter-related complications. Drew and colleagues studied the efficacy and safety of oral ganciclovir for the treatment of cytomegalovirus retini...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Use of oral ganciclovir for cytomegalovirus retinitis. (adapted from the New England Journal of Medicine 1995;333:615-20)(Tips from Other Journals)
American Family Physician ; Retinitis, a complication in 40 percent of patients with acquired immunodeficiency syndrome, may lead to partial or complete vision loss if left untreated. Intravenous ganciclovir and foscarnet are approved treatments for cytomegalovirus retinitis. However, intravenous therapy is associated with
Combination therapy boosts CMV control
Ophthalmology Times ; Oral ganciclovir used in conjunction with implant gets good results ATLANTA-The combination of oral ganciclovir administered with a ganciclovir intraocular implant has been shown to decrease the incidence of new cytomegalovirus (CMV) disease and delay progression of retinitis in patients with AIDS
New CMV treatments finally arriving for HIV patients
Drug Topics ; Treatment for cytomegalovirus (CMV) infection in HIV patients is finally getting easier. In October, the Food & Drug Administration expanded the indication for oral ganciclovir (Cytovene, Roche Bioscience) to include prevention of CMV, including CMV retinitis, in advanced AIDS patients. The
Grapefruit juice and FK506, oral ganciclovir and CMV, using both kidneys from older donors research presented at ASTP, ASTS Annual Meetings
Transplant News ; ... Edward Gene, MD, of Middlemore Hospital in Aukland, New Zealand. The transplant community has been waiting a long time for this news, Gene said. The six-month incidence of CMV disease was 19.5% in the placebo group of 152 liver transplant patients. but was only ...
HHV-6 and MS Link Warrants Further Study.(Brief Article)(Statistical Data Included)
Family Practice News ; SAN FRANCISCO -- Accumulating evidence links chronic infection with human herpesvirus 6 and multiple sclerosis. Controlling human herpesvirus 6 (HHV-6) viremia with intravenous ganciclovir was associated with resolution of multiple sclerosis (MS) symptoms in women with recent-onset disease, Dr.
Treatment of cytomegalovirus retinitis in AIDS patients.(Tips from Other Journals)
American Family Physician ; Cytomegalovirus disease affects up to 44 percent of patients with acquired immunodeficiency syndrome, generally when the patient's CD4 count is less than 50 per [mm.sup.3]. Eighty-five percent of patients with cytomegalovirus disease associated with AIDS develop retinitis. Symptoms include blurring
Cytomegalovirus infection and AIDS: value of oral ganciclovir. (adapted from the New England Journal of Medicine 1996;334:1491-7)(Tips from Other Journals)
American Family Physician ; As many as 90 percent of patients with acquired immunodeficiency syndrome have evidence of cytomegalovirus infection, especially cytomegalovirus retinitis, on autopsy. Although ganciclovir and foscarnet, two antiviral agents, are approved for the treatment of some cytomegalovirus-related
Cytomegalovirus.
American Family Physician ; Cytomegalovirus (CMV) is a prevalent pathogen, with 40 to 100 percent of the general population showing prior exposure by serology. (1) Up to 20 percent of children in the United States will have contracted CMV before puberty. Children may in turn be reinfected with different strains of the virus.
Hoffman-La Roche receives FDA clearance to market oral ganciclovir for prevention of CMV
Transplant News ; Hoffmann-La Roche, Nutley, NJ, announced it has received clearance from the Food and Drug Administration (FDA) to market oral ganciclovir (Cytovene (R) capsules) for the prevention of cytomegalovirus (CMV), a potentially life-threatening infection in recipients of solid organ transplants. The
Management of opportunistic infections in solid-organ transplantation
Progress in Transplantation ; Solid-organ transplantation is often the last alternative in many patients with end-stage organ disease. Although advances in immunosuppressive regimens, surgical techniques, organ preservation, and overall management of transplant recipients have improved graft and patient survival, infectious